Drug intelligence / Profile preview

EP-00033

Development stage: Preclinical
Lead developer: Therorna
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

EP-00033 is a circular RNA (circRNA) therapeutic candidate being developed by Yuanyin (Beijing) Biotechnology (also known as Therorna) for the treatment of multiple autoimmune diseases. Leveraging Therorna's proprietary circRNA platform, EP-00033 is designed to express therapeutic proteins or modulate immune pathways with enhanced stability and prolonged expression compared to traditional linear mRNA. The program is currently in the preclinical discovery stage.

Targets

CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on EP-00033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-00033.